[{"id":"8d0a86bc-2a9f-48de-ba1a-c4706a3277cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00045942","created_at":"2021-01-17T17:24:36.474Z","updated_at":"2024-07-02T16:37:18.951Z","phase":"Phase 2","brief_title":"PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)","source_id_and_acronym":"NCT00045942","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 D835Y • FLT3 D835","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 D835Y • FLT3 D835"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • itraconazole"],"overall_status":"Completed","enrollment":" Enrollment 144","initiation":"Initiation: 01/30/2002","start_date":" 01/30/2002","primary_txt":" Primary completion: 03/27/2008","primary_completion_date":" 03/27/2008","study_txt":" Completion: 03/27/2008","study_completion_date":" 03/27/2008","last_update_posted":"2017-08-11"}]